{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:44Z","timestamp":1790902484892,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ero.2025.12.017","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:49:22Z","timestamp":1769312962000},"page":"100116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of venanprubart, a BTLA agonist antibody, in patients with active systemic lupus erythematosus"],"prefix":"10.1016","volume":"2","author":[{"given":"Indrajit","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer W.","family":"Witcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz-Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Linnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6466-348X","authenticated-orcid":false,"given":"Andrew C.","family":"Vendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2025.12.017_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.ero.2025.12.017_bib0002","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ero.2025.12.017_bib0003","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ero.2025.12.017_bib0004","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ero.2025.12.017_bib0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev-immunol-030409-101202","article-title":"Slow down and survive: enigmatic immunoregulation by BTLA and HVEM","volume":"28","author":"Murphy","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.ero.2025.12.017_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1073\/pnas.0409071102","article-title":"A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator","volume":"102","author":"Gonzalez","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ero.2025.12.017_bib0007","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ni1144","article-title":"B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator","volume":"6","author":"Sedy","year":"2005","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.ero.2025.12.017_bib0008","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.4049\/jimmunol.182.3.1509","article-title":"B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK","volume":"182","author":"Vendel","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ero.2025.12.017_bib0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.3282","article-title":"Godzik A. B- and T-lymphocyte attenuator in systemic lupus erythematosus disease pathogenesis","volume":"116","author":"Vendel","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ero.2025.12.017_bib0010","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1084\/jem.20102017","article-title":"Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression","volume":"207","author":"Albring","year":"2010","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ero.2025.12.017_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/rheumatology\/kex368","article-title":"Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index","volume":"57","author":"Kalunian","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ero.2025.12.017_bib0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jimmun\/vkae057","article-title":"Quantitative detection of the HVEM-BTLA checkpoint receptor cis-complex in human lymphocytes","volume":"214","author":"Atwell","year":"2025","journal-title":"J Immunol"},{"issue":"suppl 1","key":"10.1016\/j.ero.2025.12.017_bib0013","article-title":"42 Gene expression profile from 1,760 sle patients reveals novel complex interferon responsive gene networks","volume":"4","author":"Hoffman","year":"2017","journal-title":"Lupus Sci Med"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:17:25Z","timestamp":1790900245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125001521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050708125001521"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.12.017","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of venanprubart, a BTLA agonist antibody, in patients with active systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100116"}}